Overview

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).

Eligibility

Inclusion Criteria:

• Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines.
• Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
• Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.

Exclusion Criteria:

• Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening, according to the Investigator's discretion.
• Use of certain medications.
• History of diseases with urticaria or angioedema symptoms, other than CSU and symptomatic dermographism.
• Significant medical history other than CSU, or any other condition which might interfere with the evaluation of CSU.